Madrigal Pharma (MDGL) Confirms FDA Approval of Rezdiffra for Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

Visit StreetInsider.com at http://www.streetinsider.com/Trading+Halts/Madrigal+Pharma+%28MDGL%29+Confirms+FDA+Approval+of+Rezdiffra+for+Treatment+of+Patients+with+Noncirrhotic+NASH+with+Moderate+to+Advanced+Liver+Fibrosis/22933126.html for the full story.

Leave a Reply

Your email address will not be published. Required fields are marked *